Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adl-5747 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 15/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.84 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adl-5747 Free Base SCHEMBL29457720 | 1.00 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471589 | 0.96 | OPRD1 (0.93) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471638 | 0.94 | OPRD1 (0.89) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471412 | 0.91 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL10258888 | 0.90 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471410 | 0.89 | OPRD1 (0.80) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471533 | 0.88 | OPRD1 (0.78) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL467302 | 0.87 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL471337 | 0.86 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL2071898 | 0.86 | OPRD1 (0.98) | OPRD1KCNH2CYP2D6OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675847-B1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2012-12-05 | — | — | EP | claimed |
| US-7638527-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-12-29 | — | — | US | claimed |
| EP-1675847-A4 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2008-08-20 | — | — | EP | claimed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | claimed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| JP-2007507532-A | — | — | 2007-03-29 | — | — | JP | claimed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | claimed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | claimed |
| EP-4704874-A2 | MOLECULES AND METHODS OF USE THEREOF | Woolwich Sciences LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226545-A2 | MOLECULES AND METHODS OF USE THEREOF | WOOLWICH SCIENCES LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-1675847-B1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | disclosed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.